Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Glossary Glossary
The Body Covers: The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy
I-97: d4T, ddI and Nevirapine (NVP) in Antiretroviral-Naïve Patients: A Convenient Triple Regimen

September 26, 1998

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

This open label French study enrolled 60 antiretroviral naïve patients, who had baseline plasma HIV RNA levels of greater than 25,000 copies/ml and CD4 counts greater than 200 cells/mm3. The median CD4 count at baseline was 434 cells/mm3, and HIV RNA 108,800 copies/ml. The mean viral load decrease was -1.9 logs by week 4 and continued through week 24; and 84% of the patients had plasma viral loads less than 500 copies/ml by week 16. The median CD4 cell increase was 129 by week 16. 22% of patients developed cutaneous rash with a mean of 15 days for rash to develop after drug initiation (range 3-26 days); this led to NVP discontinuation in 4/13 patients. 2 patients discontinued the regimen because of abnormal liver function tests. The presentation suggested that d4T, ddI, and nevirapine given in combination can be a very effective protease inhibitor sparing regimen, with minimal and manageable side effects.

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Reference

Abstract: d4T, ddI and nevirapine (NVP) in antiretroviral-naïve patients: a convenient triple regimen
Authored by: Raffi et al

See Also
HIV Medications: When to Start and What to Take -- A Guide From TheBody.com
More Research on First-Line HIV Treatment



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement